Research programme: SB 9200/nucleotide/nucleoside analogue - Spring Bank Pharmaceuticals

Drug Profile

Research programme: SB 9200/nucleotide/nucleoside analogue - Spring Bank Pharmaceuticals

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Class Antivirals; Nucleosides; Nucleotides
  • Mechanism of Action DDX58 protein stimulants; Immunostimulants; NOD2 protein antagonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 01 Aug 2016 Preclinical trials in Hepatitis B in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top